Company Heidelberg Pharma AG

Equities

HPHA

DE000A11QVV0

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

Real-time Estimate Tradegate Other stock markets 03:30:00 2024-04-19 am EDT			5-day change	1st Jan Change
3 ^EUR	+1.35%		0.00%	-18.45%

Mar. 27	Heidelberg Pharma Wins US FDA Orphan Drug Designation for Multiple Myeloma Treatment	MT
Mar. 25	Transcript : Heidelberg Pharma AG, 2023 Earnings Call, Mar 25, 2024

Heidelberg Pharma AG, formerly Wilex AG, is a Germany-based Company, which is engaged in the biopharmaceuticals sector. The Company focuses on the research and development of therapy treatments for oncology area. It aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Companyâs pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. It also offers preclinical contract research services.

Number of employees: 95

EUR in Million	2022	Weight	2023	Weight	Delta
Antibody Drug Conjugates 100.0 %	19	100.0 %	10	100.0 %	-46.75%

EUR in Million	2022	Weight	2023	Weight	Delta
China 48.1 %	8	44.3 %	5	48.1 %	-42.22%
United States 47.4 %	9	48.5 %	5	47.4 %	-47.98%
Rest of the World 2.5 %	1	3.9 %	0	2.5 %	-66.71%
Switzerland 1.5 %	0	0.3 %	0	1.5 %	+178.85%
Germany 0.6 %	1	3.0 %	0	0.6 %	-89.07%

Managers	Title	Age	Since
Andreas Pahl CEO	Chief Executive Officer	-	11-12-31
Walter Miller DFI	Director of Finance/CFO	-	23-04-30
András Strassz CTO	Chief Tech/Sci/R&D Officer	-	21-02-28
Jörg Kemkowski COO	Chief Operating Officer	-	22-12-31
Sylvia Wimmer IRC	Investor Relations Contact	-	99-11-30
George Badescu PRN	Corporate Officer/Principal	-	21-10-31

Members of the board	Title	Age	Since
Friedrich von Bohlen und Halbach BRD	Director/Board Member	60	05-04-28
Georg F. Baur BRD	Director/Board Member	74	00-12-13
Birgit Kudlek BRD	Director/Board Member	57	12-05-24
Christof Hettich CHM	Chairman	64	10-05-20
Mathias Hothum BRD	Director/Board Member	58	15-07-29
Dong Zhou Liu BRD	Director/Board Member	-	22-06-27

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	46,604,977	7,896,350 ( 16.94 %)	0	16.94 %

Name	Equities	%	Valuation
dievini Hopp BioTech holding GmbH & Co. KG 45.65 %	21,272,881	45.65 %	72 M €
HUADONG MEDICINE CO., LTD 34.99 %	16,304,560	34.99 %	55 M €
UCB 2.427 %	1,131,186	2.427 %	4 M €
Private VermögensVerwaltung AG 0.0536 %	25,000	0.0536 %	84 240 €
Financière Arbevel SA 0.0288 %	13,400	0.0288 %	45 153 €
Ampega Investment GmbH 0.0278 %	12,947	0.0278 %	43 626 €
Gutmann Finanz Strategien AG 0.0137 %	6,400	0.0137 %	21 565 €
BayernInvest Kapitalverwaltungsgesellschaft mbH 0.000577 %	269	0.000577 %	906 €

Heidelberg Pharma AG

Gregor-Mendel-Strasse 22

68526, Ladenburg

+49 6203 1009 0

http://heidelberg-pharma.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.96 EUR

Average target price

11.3 EUR

Spread / Average Target

+281.76%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
HEIDELBERG PHARMA AG	-20.86%	147M
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.07B
ARGENX SE	-0.44%	21.66B
BIONTECH SE	-18.35%	20.77B
GENMAB A/S	-7.45%	18.53B
WUXI APPTEC CO., LTD.	-40.31%	16.91B
BEIGENE, LTD.	-26.84%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.33B
SAREPTA THERAPEUTICS, INC.	+20.86%	10.94B

Bio Therapeutic Drugs